BCL2 and glioblastoma: Gossypol (AT-101) tested in GBM treatment, binds to BH3 domains of Bcl-2, Bcl-xl, and Mcl-1, and is reported to efficiently inhibit in vitro and in vivo growth of glial tumors [11].